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EVALUATION OF A WIRELESS HANDHELD MEDICATION MANAGEMENT
PROGRAM IN THE PREVENTION OF DRUG-DRUG INTERACTIONS
Saverno K, Malone DC
University of Arizona College of Pharmacy, Tucson, AZ, USA
OBJECTIVES: Drug-related adverse events impose a substantial burden on patients 
and health care systems. Electronic prescribing (e-prescribing) systems have been 
identiﬁ ed as effective tools to improve quality, safety, and efﬁ ciency in health care
delivery. The purpose of this study is to evaluate the effectiveness of a wireless
medication management program in a commercially available e-prescribing system in 
the prevention of serious drug-drug interactions (DDIs). METHODS: This study 
employed a retrospective pre-post with a control group design to evaluate the effective-
ness of wireless handled medication management program in preventing serious DDIs.
A total of 1975 prescribers who received personal digital assistants (PDA) between
August 1, 2004 and June 30, 2005 constituted the technology user group. The com-
parison group included 1063 prescribers who sent a request to obtain, but did not
receive, the technology during the same period. Multivariate regression analysis was 
used to determine if there were differences between the two groups of prescribers in 
the rate of prescribing clinically important DDIs. RESULTS: Prescribers in the two 
groups were signiﬁ cantly different in their specialty practice areas and number of 
pharmacy claims and at baseline. However both groups were similar in their average 
age, profession, and practice type. Prescribers varied in their use of the e-prescribing 
system to access patient medication history, the average number of patient medication 
history updates requested per prescriber in the user group was 42.09 (ranging from 0
to 1073). The most widely prescribed DDIs included those involving warfarin with 
non steroidal anti-inﬂ ammatory drugs (NSAIDs) and anticoagulants with thyroid 
hormones. Compared to the control group, PDA users did not have signiﬁ cantly 
greater decrease in the number of serious potential DDIs as compared to non users
(p  0.65). CONCLUSIONS: The availability of near real-time patient medication
history did not have a signiﬁ cant impact on reducing the rate of prescribing clinically 
important DDIs.
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PRESCRIPTION PATTERNS OF CHINESE HERBAL PRODUCTS 
SUSPECTED OF CONTAINING ARISTOLOCHIC ACID: ANALYSIS OF
REIMBURSEMENT DATA OF A COHORT FROM TAIWAN DURING
1997–2003
Hsieh SC1, Wang JD2
1Center for Drug Evaluation, Taipei City, Taiwan, 2National Taiwan University, College of Public
Health, Taipei, Taiwan
OBJECTIVES: Although the nephrotoxic and carcinogenic effects of Aristolochic
acid (AA) have already been well documented, there is a distinct lack of evidence
on the long-term consumption of Chinese herbal products (CHPs) which either
contain Aristolochia herb species, or which have been adulterated by herbs suspected
of containing AA (SAA herbs). We set out to identify the risks and to determine the 
prescription patterns in Taiwan of CHPs containing SAA herbs (SAA CHPs) prior to 
the promulgation of the regulations banning their use. METHODS: A longitudinal 
analysis was carried out on a randomly sampled cohort of 200,000 patients using
1997–2003 data obtained from the Taiwan National Health Insurance (NHI) reim-
bursement database. RESULTS: During the seven-year study period, a total of 
78,644 patients had been prescribed with SAA CHPs on at least one occasion, the
majority of whom were females and/or middle-aged. A total of 526,867 prescriptions
were issued containing 1,218 licensed SAA CHP items. Over 85% of SAA-exposed 
patients took less than 60 gms of SAA herbs; however, about 7% were exposed to a 
cumulative dose in excess of 100 gms of Xi xin, Mu tong or Ma dou ling. Diseases
of the respiratory and musculoskeletal system were the most common indications 
for the SAA CHP prescriptions. The most frequently prescribed SAA CHPs were 
Shu jing huo xie tang, Chuan qiong cha diao san, and Long dan xie gan tang, respec-
tively containing Fang ji, Xi xin, and Mu tong. CONCLUSIONS: About one-third 
of people in Taiwan have at some time been prescribed with SAA CHPs, and
although the cumulated dosages may not be large, future studies are indicated to 
safeguard CHP usage.
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WHEN COMPARATIVE EVIDENCE IS UNCERTAIN: USE OF
QUANTITATIVE CONSENSUS METHODS TO FILL IN GAPS
Miller RM, Dubois R
Cerner LifeSciences, Beverly Hills, CA, USA
OBJECTIVES: In creating economic models or reimbursement dossiers, gaps in evi-
dence inevitably arise. Typically, these gaps are addressed in a non-systematic and 
non-quantitative manner, leading to inter-expert variability and disagreement amongst
clinicians and decision-makers. The RAND Appropriateness Method is a validated,
structured multi-round Delphi consensus process that we have adapted to US and ex-
US expert panels with broad stakeholders including varying groups of both clinicians 
and payers. We have successfully applied this adapted technique across multiple topics
including diabetes, cancer, depression, and Alzheimer’s disease. METHODS: Partici-
pants reviewed published evidence, guidelines and community practice data and com-
pleted multi-round ratings (9-point scale) with individual and group feedback. Panels
rated (and sometimes ranked) in pre- and post-fashion the likelihood and importance
of selected clinical and/or patient-reported outcomes, as well as the level of scientiﬁ c 
evidence and appropriateness of therapeutic options to address them. Median scores 
and measures of dispersion/disagreement were calculated for each round of ratings.
RESULTS: Utilizing this method consistently resulted in a lower median opinion post-
rating of importance and/or decision categories that are “based on their own experi-
ences or that of their peers” – i.e. a change to more evidence-based decisions rather 
than anecdotal. Additionally, while round 1 ratings often had high disagreement rates
between payers and clinicians or between different treating clinicians, those rates of 
disagreement fell after evidence review and discussion. Moreover, using this method,
payer experts were able to create narrower parameter estimates for the prevalence of 
disease complications and its resulting mortality for use in economic modeling.
Although pre-ratings of value messages were highly variable, payers’ post-evaluation 
ratings after evidence review had less variability and higher (more compelling) scores.
CONCLUSIONS: Use of quantitative consensus processes can minimize idiosyncratic
variation among experts and create a more reliable connection between evidence and 
decision making.
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MEDICATION ADMINISTRATION PROCESS CONDUCTED BY NURSES
IN INTENSIVE AND ACUTE CARE UNITS OF A HOSPITAL: A TIME AND
MOTION STUDY
Dasgupta A1, Sansgiry S2, Frost C3, Tipton J3, Sherer J2
1University of Texas at Austin, Austin, TX, USA, 2University of Houston, Houston, TX, USA, 3St. 
Luke’s Episcopal Hospital, Houston, TX, USA
OBJECTIVES: To determine workﬂ ow variables associated with medication adminis-
tration process conducted by nurses in intensive and acute care units of a hospital. 
METHODS: A time-and-motion study was conducted in intensive and acute care units 
of a hospital. Each medication administration was operationalised as a combination 
of ﬁ ve activities namely direct patient care (ﬁ ve tasks), indirect patient care (four tasks), 
administration (four tasks), miscellaneous (three tasks) and other. Time devoted to 
each medication administration and each task were evaluated by means of two pre-
calibrated stop-watches. Perception of nurses regarding workﬂ ow burden during each 
medication administration was determined on a ﬁ ve point Likert scale as strongly dis-
agree (1)—Strongly agree (5). Furthermore patient features (age, gender, number of 
co-morbidities, length of stay) and complexity of medication administration (frequency 
of each task, number of assistants involved, number of drugs administered through 
different routes) were used to predict medication administration time. Descriptive sta-
tistics were reported. Stepwise regression analysis was performed to examine predictors 
of medication administration time. RESULTS: Mean medication administration time 
in intensive (N  101) and acute (N  100) care units were 5.2 o 3.7 minutes and 5.3 
o 3.5 minutes respectively. Overall nurses had positive perception regarding the sup-
portive workﬂ ow structure of intensive (4.4 o 0.08) and acute care (4.6 o 0.5) units. 
Stepwise regression analysis indicated that signiﬁ cant (p  0.05) predictors of medica-
tion administration time in intensive care unit were time devoted to administration 
(B  0.57), direct patient care (B  0.30), and miscellaneous (B  0.14) activities. Like-
wise signiﬁ cant (p  0.05) predictors of medication administration time in acute
care unit were time devoted to administration activity (B  0.67), gender of patient
(B  0.21) and number of inhaled drugs administered (B  0.16). CONCLUSIONS:
Administration activity played a predominant role during medication administration 
in both units. Measures taken by hospital pharmacy to optimize such an activity may 
result in reduction of workﬂ ow burden encountered by nurses in the units.
DIABETES/ENDOCRINE DISORDERS – Clinical Outcomes Studies
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LITERATURE REVIEW OF THE IMPACT OF OBESITY ON
CARDIOVASCULAR OUTCOMES IN THE GENERAL POPULATION AND 
IN PATIENTS WITH TYPE-2 DIABETES
Smith-Palmer J1, Kalsekar A2, Boye KS2, Goodall G1
1IMS Health, Basel, Switzerland, 2Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: There is an established causal link between obesity and cardiovascular
outcomes. The aim of this review was to determine whether an independent relation-
ship exists between anthropometric measurements of weight (typically body mass
index [BMI]) and cardiovascular outcomes (e.g., angina, myocardial infarction, con-
gestive heart failure, stroke, mortality) in the general population and in patients
with type-2 diabetes. METHODS: A review of the medical literature was conducted
between 1988 and May 2008 using the PubMed, EMBASE, Cochrane and Center for
Review and Dissemination databases. We included studies that were longer than 12 
months, had greater than 500 adult subjects and were written in the English language. 
RESULTS: In studies conducted in general populations there was an overall trend 
towards increased risk for cardiovascular outcomes with increasing BMI. However, a
few studies reported a J-shaped or U-shaped between BMI measurements and cardio-
vascular events. The nature and strength of this relationship varied according to the 
measurement used (e.g., BMI, waist circumference, waist-to-hip ratio) and the popula-
tion studied, with notable differences observed in Asian/Asia-Paciﬁ c based studies 
compared with those conducted in European or North American populations. There
was limited data from prospective, long-term, longitudinal studies examining the 
relationship between degrees of weight and cardiovascular disease in patients with
type-2 diabetes. CONCLUSIONS: In general, the degree of being overweight or obese
